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Background: To investigate the expression of Golgi phosphoprotein-3 (GOLPH3) in prostate cancer and determine
its prognostic value.
Methods: Immunohistochemical staining for GOLPH3 was performed on tissue microarrays of 342 prostate patients.
The correlation between GOLPH3 expression with its clinicopathologic factors was also analyzed in order to
determine its prognostic significance.
Results: GOLPH3 expression of normal prostate tissues, benign prostate hyperplasia, high-grade prostatic
intraepithelial neoplasia, and hormone-dependent prostate cancer (HDPC) did not show any statistically significant
difference. In contrast, statistically significant difference was reported in moderate/intense GOLPH3 expression in
cases diagnosed with HDPC and castration resistant prostate cancer (CRPC) (P < 0.0005). Moderate /intense
expression of GOLPH3 was associated with androgen independence (P= 0.012), higher Gleason score (P= 0.017),
bone metastasis (P= 0.024), higher baseline prostate-specific antigen (PSA) (P= 0.038), and higher PSA nadir
(P= 0.032). A significantly negative correlation was found between moderate/intense GOLPH3 expression and
disease-free survival (DFS) (HR = 0.28, P= 0.012) and overall survival (OS) (HR = 0.42, P= 0.027). Univariated analysis
indicated that moderate/intense GOLPH3 expression created a significantly prognostic impact in patients with
CRPC. On the other hand, multivariate analysis indicated that GOLPH3 was a significantly independent prognostic
factor of DFS (P= 0.027) in all prostate cancer patients.
Conclusions: In this study, it was discovered that the overexpression of GOLPH3 is associated with the transition of
prostate cancer from hormone sensitive phase to hormone refractory phase. GOLPH3 might be an important
prognostic factor of DFS and OS in patients with prostate cancer. In totality, GOLPH3 could be used as a novel
candidate in devising a more effective therapeutic strategy to tackle CRPC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1452541171722856.
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Prostate cancer is a major public health problem. Accord-
ing to reported estimates, prostate cancer is regarded as
the second most common malignancy among men resid-
ing in the European Union and North America. In recent
years, the morbidity rate of prostate cancer has been in-
creasing steadily in China. For example, the annual mor-
bidity rate of prostate cancer has increased by 14% since
1990. In contrast, the annual morbidity rate was quite
stable in the 1970s and 1980s [1].
Most cases of prostate cancer are responsive to andro-
gen ablation therapy in the initial stages. However, many
tumors eventually become androgen-refractory. Thus,
these tumors become resistant to hormonal therapy with
the passage of time. Eventually, metastatic phenotypes
proliferate in patients suffering from prostate cancer [2].
We have not been successful in devising an effective thera-
peutic approach to tackle cases of castration resistant
prostate cancer (CRPC). In fact, few biomarkers are cap-
able of reasonably distinguishing aggressive and non-
aggressive tumors after diagnosis. In other words, biomar-
kers with greater sensitivity and specificity can provide evi-
dences for the diagnosis and prognosis of CRPC [3,4].
Golgi phosphoprotein-3 (GOLPH3) has several alterna-
tive names, such as GPP34, GMx33, MIDAS, and yeast
Vps74p. It is a member of the trans-Golgi matrix family
and binds to PtdIns(4)P-rich trans-Golgi membranes and
MYO18A. This indicates that a tensile force is required for
efficient tubule and vesicle formation [5,6]. Recently, sev-
eral evidences suggest that GOLPH3 is an oncogene, repre-
senting a first-in-class Golgi oncoprotein. GOLPH3, a
novel oncogene, is commonly targeted for amplification in
human cancer. Note that, an enhanced activation of
mTOR signaling represents a molecular basis of GOLPH3’s
oncogenic activity [7,8]. However, research studies have
seldom studied the correlation between GOLPH3 expres-
sion and prognosis of Chinese patients with prostate can-
cer. In fact, very few studies have explored the transition
from hormone-sensitive prostate cancer to CRPC. Taking
this fact into consideration, we performed immunohisto-
chemical assay to evaluate the expression of GOLPH3 in
definite tissues. We also carried out retrospective follow-
up analysis to explore the correlation between GOLPH3
expression and clinicopathologic factors associated with
the prognosis of Chinese patients with prostate cancer.
Materials and methods
We used the surgical prostate cancer database to retro-
spectively evaluate 342 patients. In the period extending
from October 2002 to December 2009, these patients
had undergone prostatectomy, transrectal prostate bi-
opsy under ultrasound guidance, or transurethral resec-
tion of the prostate. Among the 342 patients, 139
(36.48%) suffered from hormone-dependent prostatecancer (HDPC). On the other hand, 102 (26.77%)
patients were diagnosed with CRPC. 61 (16.01%) cases
were diagnosed with high-grade prostatic intraepithelial
neoplasia (HGPIN). 20 (5.25%) patients were diagnosed
with benign prostate hyperplasia (BPH), while 20
(5.25%) cases were normal prostate tissue subjected to
pancystectomy. All the specimens were fixed with for-
malin and embedded in paraffin. All the slides were
blindly reviewed by five pathologists, and a consensus
diagnosis was reached.
Clinical data, including Gleason score, baseline
prostate-specific antigen (PSA), prostate-specific antigen
nadir, bone metastasis, and follow-up status, were retro-
spectively obtained from Hospital Medical Records
Room. On the other hand, paraffin-embedded prostate
tissues were obtained from the Department of Pathology,
the Fourth Affiliated Hospital of Jinan University,
Guangzhou, China. The data analysis was approved by
our hospital review board.
Tissue microarrays were constructed according to the
previously described procedure [9]. Briefly, representa-
tive areas of prostate tissue from each of the 342 cases
were identified on the corresponding slides stained with
hematoxylin and eosin. Tissue cylinders with 1 mm
diameter were punched from each donor tissue block so
that they could penetrate into a recipient paraffin block.
A tissue microarrayer was used in this procedure. The
recipient paraffin block was subsequently cut, and the
slices were transferred onto coated slides using adhesive
tape. Then, the slides were dipped in paraffin to prevent
oxidation. With the objective of minimizing tissue loss
and problems associated with tumor heterogeneity, every
sample was arrayed in triplicates.
To determine the immunohistochemistry of these tis-
sues, tissue microarray sections were stained and
GOLPH3 expression was determined according to the
procedure described in previous studies [10]. In sum-
mary, the primary antibody was raised against GOLPH3
(ProteinTech Group, Inc.; Cat#:19112-1-AP; 1:100 dilu-
tion). Staining for GOLPH3 was reckoned as positive
provided cytoplasmic staining was observed in more
than 10% of definite cells. In cases of positive staining,
the intensity of stain were recorded as either weak (1+),
moderate (2+), or intense (3+).
Statistical analysis was performed using SPSS16.0 soft-
ware. Chi-square test was used to investigate the signifi-
cance of the relationship between GOLPH3 and the
individual variables. The relationship between GOLPH3
expression and their clinical outcomes was estimated
through both univariate and multivariate analyses. The
disease-free survival (DFS) and overall survival (OS)
curves were estimated using the Kaplan Meier method,
while the differences in the survival curves were com-
pared using the log-rank test. A multivariate analysis
Figure 1 Representative H&E and immunohistochemical staining results for GOLPH3 (HE x200, IHC x400). A CRPC, H&E staining. B CRPC,
GOLPH3(+++), IHC staining; C HDPC, H&E staining. D HDPC, GOLPH3(+), IHC staining; E HGPIN, H&E staining. F HGPIN, GOLPH3(+), IHC staining;
G BPH, H&E staining. H BPH, GOLPH3(+), IHC staining; I Normal prostate tissue, H&E staining. J Normal prostate tissue, GOLPH3(+), IHC staining.
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Table 1 Clinicopathologic characteristics of patients according to GOLPH3 status
Characteristics Intensity of GOLPH3 expression
NNegative % Positive
Weak (1+) % Intense/moderate(2+/3+) % P-value
Number 8 2.34 239 69.88 95 27.78 —
Age,year
≤60 2 4.35 37 80.43 7 15.22 0.204
>60 11 3.72 198 66.89 87 29.39
Gleason score <0.001
Gleason 2-6 5 15.15 21 63.64 7 21.21
Gleason 7 3 2.29 109 83.21 19 14.50
Gleason 8-10 4 5.20 22 28.57 51 66.23
PC
CRPC 4 3.92 15 14.71 83 81.37 <0.0005
HDPC 5 3.60 119 85.61 15 10.79
HGPIN and Nor
BPH 0 0 19 95.00 1 5.00 0.970
HGPIN 1 1.64 57 93.44 3 4.92
Normal tissue 1 5.00 18 90.00 1 5.00
Table 2 Correlationship between clinicopathologic
characteristics of patients and intensity of GOLPH3
expression
Characteristics Intensity of GOLPH3 expression
P value C value
Androgen dependence 0.012 0.144
Yes
No




Bone metastasis 0.024 0.398
Yes
No
Baseline PSA 0.038 0.181
≤10ng/ml
>10ng/ml
PSA nadir 0.032 0.312
≤1ng/ml
>1ng/ml
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≤0.05 were of statistical significance.
Results
In the 342 cases investigated in this study, distinct
immunohistochemical staining (negative, 1+, 2+, or 3+)
of GOLPH3 was reported (Figure 1). The association of
the immunophenotype of GOLPH3 with various clinico-
pathological parameters has been enlisted in Table 1.
As shown in Table 1, 18 (90%) out of 20 cases of normal
prostate tissue, 19 (95%) out of 20 cases of BPH, and 56
(92%) out of 61 cases of HGPIN showed weak (1+) expres-
sion of GOLPH3. There were no statistically significant
differences in GOLPH3 expression of BPH, normal pros-
tate tissues, or HGPIN. 83 (81.37%) of 102 CRPC cases
showed moderate/intense expression for GOLPH3,
whereas 15 (14.71%) cases were detected with weak ex-
pression. On the other hand, 4 (3.92%) cases showed nega-
tive results for GOLPH3 expression. 15 (10.79%) of 139
HDPC cases showed moderate/intense expression of
GOLPH3, while 119 (85.61%) reported weak expression.
In contrast, 5 (3.60%) cases were tested negative for
GOLPH3 expression. Moreover, moderate/intense expres-
sion of GOLPH3 was found in 3 (4.92%) of 61 HGPIN, 1
(5%) of 20 BPH cases, and 1 (5%) of 20 normal prostate
tissue. There were statistically significant differences in
GOLPH3 expression (moderate/intense) of CRPC and
HDPC (P < 0.0005). In contrast, there was no statistical
difference in GOLPH3 expression (moderate/intense) of
HDPC and HGPIN, BPH, and normal prostate tissue.
Moderate/intense expression of GOLPH3 was reported inCRPC cases (P=0.012). As shown in Table 2, CRPC cases
also reported higher Gleason score (P=0.017), bone me-
tastasis (P=0.024), higher baseline PSA (P=0.038), and
higher PSA nadir (P=0.032) .
According to statistical research reports of June 2010,
the average follow-up time was 38.5 months (range,
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cancer, 44 (18.26%) were lost to follow-up and 31 (12.86%)
succumbed to death. In the five-year period, the DFS and
OS rates were 68.2 and 71.6%, respectively. All the
241 prostate cancer patients were examined to deter-
mine their GOLPH3 status. In the five-year period, the
DFS rates of patients with moderate/intense GOLPH3
expression was 43.1%. On the other hand, DFS rates for
patients with weak GOLPH3 expression was 87.2% dur-
ing the five-year study period. The overall survival rate
of patients with moderate/intense GOLPH3 expression
was 45.4%. But, the overall survival rate of patients with
weak GOLPH3 expression was 89.3%. Compared to
patients with moderate/intense GOLPH3 expression,
patients with weak GOLPH3 expression had a signifi-
cant longer DFS (HR=0.28, P= 0.012) and OS (HR=0.42,
P=0.027; data not shown) (Figure 2).
Table 3 enlists the statistically significant predictors of
DFS within the univariate analysis. Higher Gleason score,
higher prostate-specific antigen nadir, positive bone me-
tastasis, and moderate/intense positive GOLPH3 expres-
sion were the parameters that were correlated with
shorter DFS. Compared to patients with intense or moder-
ate GOLPH3 expression, the patients whose tumor cells
showed weak expression of GOLPH3 had significantly bet-
ter outcomes in terms of DFS (P<0.001). In the multivari-
ate analysis, moderate/intense GOLPH3 expression
continued to be a significant predictor of DFS while simu-
lating a model containing all the clinicopathologic vari-
ables (P=0.027; Table 3).
Discussion
Prostate cancer is a serious illness that continues to
present several different challenges to the urologists,
pathologists, radiologists and oncologists [11]. In recent
times, the incidence rate of prostate cancer has been
steadily increasing in China. Prostate cancer is the most
common non-dermatologic cancer. Despite the highFigure 2 Disease-free survival (A) and overall survival (B) curves accoincidence rate of prostate cancer, its clinical course of
treatment is often unpredictable [12,13]. While treating
prostate cancer at an advanced stage, patients are sub-
jected to surgical or pharmacological castration. This is
the most widely accepted method of treating prostate
cancer at an advanced stage. However, the prostate
tumor becomes hormone refractory after a period of 14
to 36 months. As the prostate tumor undergoes a transi-
tion from the hormone refractory stage to metastatic
stage, it poses severe problems in clinical management
[14]. Gleason score [15], PSA [16,17], clinical stage, and
prostate volume are crucial parameters that need to be
considered in the treatment of prostate cancer. Gleason
score is an important prognostic factor for predicting
biochemical failure, systemic recurrence, and overall pa-
tient survival [18]. However, there may be variations in
comprehending the Gleason score among pathologists
[19]. Note that, elevated levels of PSA can also be asso-
ciated with BPH and prostatitis [20]. Therefore, these
biomarkers seem inadequate to precisely determine the
possibility of recurrence or metastasis. Therefore, the
underlying molecular mechanisms of prostate carcino-
genesis should be further investigated and elucidated.
These efforts will help us in finding a reliable biomarker
that can help us in improving the evaluation and prog-
nosis of patients with CRPC [21].
In this study, GOLPH3 expression was detected in most
benign and malignant tissues. It is interesting to note that
98 (40.66%) of 241 prostate cancer showed GOLPH3
moderate/intense expression. This result confirmed the
findings of previous studies that reported an over expres-
sion of GOLPH3 in 37% of prostate cancer cases [7].
Progression to androgen-independence is a complex
process involving various combinations of clonal selec-
tion [22], adaptive up-regulation of anti-apoptotic genes
[23-25], androgen receptor transactivation in the ab-
sence of androgen or increased levels of coactivators
[26,27], and alternative growth factor pathways [27,28].rding to the intensity of GOLPH3 expression.
Table 3 Univariate and multivariate analyses of disease-free survival in prostate patients
Variables Univariate Multivariate
HR 95%CI P value HR 95%CI P value
Age,year (≤60 vs>60) 0.87 0.51-1.46 0.238 0.81 0.46-1.61 0.312
Gleasone Score (2–6 vs 7 or 8–10) 4.37 2.64-5.81 <0.001 5.04 3.61-6.47 <0.001
Bone metastasis (Yes vs No) 5.56 3.67-7.02 <0.001 5.44 3.46-7.11 <0.001
Baseline PSA (≤10 vs>10ng/ml) 3.24 1.89-4.51 <0.001 3.03 1.94-5.74 <0.001
PSA nadir (≤1 vs 1ng/ml) 4.21 2.97-5.84 <0.001 4.76 3.43-6.56 <0.001
Androgen dependence (Yes vs No) 0.64 0.37-1.53 <0.001 0.71 0.44-1.49 <0.001
GOLPH3 (++/+++ vs +) 0.45 0.34-0.69 0.004 0.54 0.41-0.69 0.027
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ence was found in GOLPH3 expression of normal pros-
tate tissue, BPH, and HDPC. In contrast, there was a
statistical difference in GOLPH3 expression of CRPC
and HDPC cases (p<0.0005). These findings suggested
that the oncogene GOLPH3 was highly conserved
throughout evolution. In fact, GOLPH3 was strictly
regulated in normal tissues, since it was essential for
normal cell growth. Furthermore, these data suggest the
possibility of associating the over-expression of GOLPH3
with the progression of prostate cancer. This probability
is more pronounced in the transition from hormone-
sensitive to hormone-refractory tumors. But, we cannot
decipher the correlation of GOLPH3 expression with
cellular hyperproliferation and tumorigenesis, especially
during the early stages of prostate cancer development.
mTOR is a serine/threonine protein kinase, which is
found in both rapamycin-sensitive and rapamycin-
insensitive multimeric protein complexes. To regulate
cell growth, cell-cycle progression, and cell differenti-
ation, mTOR functions as a central signal integrator that
receives signals from growth factors, nutrients, and cel-
lular energy metabolism [29,30]. Therefore, mTOR is
recognized as a central coordinator of these fundamental
biological processes [31-33]. Note that, mTOR is an evo-
lutionarily conserved protein kinase. Recent studies have
reproted that GOLPH3 works as an oncoprotein pro-
moting cell transformation and tumor growth by enhan-
cing the activity of mTOR [7]. Since mTOR is required
for cell differentiation, hyperactivation of mTOR may be
associated with abnormal cell differentiation. In conclu-
sion, an overexpression of GOLPH3 causes an abnormal
differentiation of prostate cancer cells, thereby creating
heterogeneity of tumor cells. New subclones with altered
growth properties proliferate owing to this trait of het-
erogeneity. In fact, the transition from hormone-
sensitive to hormone-refractory tumors can be probably
attributed to this molecular mechanism.
In this research study, it was found that the incidence
of Gleason score, PSA nadir, baseline PSA, and positive
bone metastasis was higher in patients detected withmoderate/intense GOLPH3 expression. In our study, we
also demonstrated that GOLPH3 over-expression was
significantly associated with a shorter DFS and OS.
Multivariate analysis revealed a significant negative rela-
tionship between the over expression of GOLPH3 and
DFS or OS. Therefore, we can conclude that GOLPH3
serves as a biomarker for predicting the severity of pros-
tate cancer. GOLPH3 expression is an important param-
eter used in the prognosis of prostate cancer patients.
In this research study, we have discovered that
GOLPH3 expression does not have any correlation with
cellular hyperproliferation and tumorigenesis, particu-
larly in the early stages of prostate cancer. On the other
hand, over-expression of GOLPH3 could be correlated
with the progression of prostate cancer from its hor-
mone sensitive phase to hormone refractory phase. Fur-
thermore, GOLPH3 might be a favorable prognostic
factor of DFS and OS in patients diagnosed with pros-
tate cancer. In this way, GOLPH3 expression serves as a
reliable prognostic marker. In fact, determining the ex-
pression of GOLPH3 might also help in further elucidat-
ing the risk of progression of prostate cancer in patients.
In conclusion, GOLPH3 can be a novel candidate for the
development of an effective therapeutic strategy for
CRPC.
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